Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Schenone

Showing results (11-20 of 173) with videos related to

Pageof 18
Sort By:
Molecules (Basel, Switzerland)|March 29, 2020
Synthesis and Biological Evaluation of Novel (thio)semicarbazone-Based Benzimidazoles as Antiviral Agents against Human Respiratory VirusesValeria Francesconi, Elena Cichero, Silvia Schenone, et al.
Expert Opinion on Therapeutic Patents|September 16, 2015
Analogs, formulations and derivatives of imatinib: a patent reviewFrancesca Musumeci, Silvia Schenone, Giancarlo Grossi, et al.
Expert Opinion on Therapeutic Patents|February 7, 2015
Bcr-Abl tyrosine kinase inhibitors: a patent reviewAndrea Desogus, Silvia Schenone, Chiara Brullo, et al.
Current Medicinal Chemistry|September 18, 2023
State-of-the-art Review on the Antiparasitic Activity of Benzimidazolebased Derivatives: Facing Malaria, Leishmaniasis, and TrypanosomiasisValeria Francesconi, Marco Rizzo, Silvia Schenone, et al.
Cancers|November 15, 2018
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid LeukemiaFrancesca Musumeci, Chiara Greco, Giancarlo Grossi, et al.
Pharmaceuticals (Basel, Switzerland)|January 20, 2021
Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer's DiseaseMarta Campora, Valeria Francesconi, Silvia Schenone, et al.
Journal of Chemical Information and Modeling|February 14, 2007
Construction and validation of a RET TK catalytic domain by homology modelingTiziano Tuccinardi, Fabrizio Manetti, Silvia Schenone, et al.
Current Pharmaceutical Design|January 22, 2013
F508del-CFTR rescue: a matter of cell stress responseErika Nieddu, Benedetta Pollarolo, Luisa Merello, et al.
Journal of Chemical Information and Modeling|May 3, 2014
Insight into the allosteric inhibition of Abl kinaseAnna Lucia Fallacara, Cristina Tintori, Marco Radi, et al.
Bioorganic & Medicinal Chemistry|May 11, 2010
Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanismsEmmanuele Crespan, Marco Radi, Samantha Zanoli, et al.
Pageof 18

Showing results (11-20 of 173) with videos related to

Sort By:
Pageof 18
Molecules (Basel, Switzerland)|March 29, 2020
Synthesis and Biological Evaluation of Novel (thio)semicarbazone-Based Benzimidazoles as Antiviral Agents against Human Respiratory VirusesValeria Francesconi, Elena Cichero, Silvia Schenone, et al.
Expert Opinion on Therapeutic Patents|September 16, 2015
Analogs, formulations and derivatives of imatinib: a patent reviewFrancesca Musumeci, Silvia Schenone, Giancarlo Grossi, et al.
Expert Opinion on Therapeutic Patents|February 7, 2015
Bcr-Abl tyrosine kinase inhibitors: a patent reviewAndrea Desogus, Silvia Schenone, Chiara Brullo, et al.
Current Medicinal Chemistry|September 18, 2023
State-of-the-art Review on the Antiparasitic Activity of Benzimidazolebased Derivatives: Facing Malaria, Leishmaniasis, and TrypanosomiasisValeria Francesconi, Marco Rizzo, Silvia Schenone, et al.
Cancers|November 15, 2018
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid LeukemiaFrancesca Musumeci, Chiara Greco, Giancarlo Grossi, et al.
Pharmaceuticals (Basel, Switzerland)|January 20, 2021
Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer's DiseaseMarta Campora, Valeria Francesconi, Silvia Schenone, et al.
Journal of Chemical Information and Modeling|February 14, 2007
Construction and validation of a RET TK catalytic domain by homology modelingTiziano Tuccinardi, Fabrizio Manetti, Silvia Schenone, et al.
Current Pharmaceutical Design|January 22, 2013
F508del-CFTR rescue: a matter of cell stress responseErika Nieddu, Benedetta Pollarolo, Luisa Merello, et al.
Journal of Chemical Information and Modeling|May 3, 2014
Insight into the allosteric inhibition of Abl kinaseAnna Lucia Fallacara, Cristina Tintori, Marco Radi, et al.
Bioorganic & Medicinal Chemistry|May 11, 2010
Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanismsEmmanuele Crespan, Marco Radi, Samantha Zanoli, et al.
Pageof 18